Premium
Scoping Review of Targeted Ultrasound Contrast Agents in the Detection of Angiogenesis
Author(s) -
Lau Christopher,
Rivas Marielena,
Dinalo Jennifer,
King Kevin,
Duddalwar Vinay
Publication year - 2020
Publication title -
journal of ultrasound in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.574
H-Index - 91
eISSN - 1550-9613
pISSN - 0278-4297
DOI - 10.1002/jum.15072
Subject(s) - medicine , angiogenesis , vascular endothelial growth factor , breast cancer , colorectal cancer , cancer research , targeted therapy , clinical trial , oncology , cancer , bioinformatics , pathology , vegf receptors , biology
A systematic search was conducted to categorize targeted ultrasound contrast agents (UCAs) used in cancer‐related angiogenesis detection. We identified 15 unique contrast agents from 2008 to March 2018. Most primary research articles studied UCAs targeted to vascular endothelial growth factor receptor or α v β 3 ‐integrin. Breast cancer and colon cancer are the most common neoplastic processes in which these agents were studied. BR55 (Bracco Research SA, Geneva, Switzerland), a vascular endothelial growth factor receptor–targeting UCA, is the first targeted UCA that has completed phase 0 trials. Our review identifies a gap in the literature regarding the application of targeted UCAs in cancer models beyond breast and colon cancers and identifies other promising UCAs.